预约演示

更新于：2025-05-07

MRSA vaccines (Abcombi Biosciences)

更新于：2025-05-07

概要

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染

在研适应症-

非在研适应症

耐甲氧西林表皮葡萄球菌（MRSE）感染

原研机构

Abcombi Biosciences, Inc.

在研机构-

非在研机构

Abcombi Biosciences, Inc.

权益机构-

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 MRSA vaccines (Abcombi Biosciences) 相关的临床结果

登录后查看更多信息

100 项与 MRSA vaccines (Abcombi Biosciences) 相关的转化医学

登录后查看更多信息

100 项与 MRSA vaccines (Abcombi Biosciences) 相关的专利（医药）

登录后查看更多信息

项与 MRSA vaccines (Abcombi Biosciences) 相关的文献（医药）

2012-12-01·Human vaccines & immunotherapeutics

Three MRSA vaccines in early clincial trials.

作者: Riedmann, Eva M

2011-02-01·Nature Medicine1区 · 医学

A MRSA-terious enemy among us: Boosting MRSA vaccines

1区 · 医学

Article

作者: DeLeo, Frank R. ; Kobayashi, Scott D.

Infection with methicillin-resistant Staphylococcus aureus (MRSA) can cause symptoms ranging from mild skin infections to more severe disease in various organs, even among healthy individuals.The ability of this pathogen to escape our immune arsenal and overcome antibiotic therapy poses a challenge to preventing their spread and treating the related symptoms.In ′Bench to Bedside′, Scott Kobayashi and Frank DeLeo explore new approaches for vaccine development that focus on antigens required for establishment of disease.Studies with infected mice immunized against S. aureus coagulases-important for abscess formation and bloodstream infection-suggest such an approach may be used to reduce bacterial load and protect against severe disease in humans.In ′Bedside to Bench′, Michael Otto examines a large human study where the presence of genes encoding Panton-Valentine leukocidin toxin (PVL) in community-associated MRSA did not correlate with complicated skin structure infections-a result opposing the widespread notion that PVL is the primary CA-MRSA virulence factor.

Vaccines

Select Whole-Cell Biofilm-Based Immunogens Protect against a Virulent Staphylococcus Isolate in a Stringent Implant Model of Infection

Article

作者: Tasker, Naomi J. P. E. R. ; Wille, Brendan P. ; Wiggins, Taralyn J. ; Tobin, Gregory J. ; Harro, Janette M. ; Tobin, John K. ; Dollery, Stephen J. ; MacLeod, David A. ; Kim, Peter C. ; Bushnell, Ruth V.

Many microbes of concern to human health remain without vaccines. We have developed a whole-microbe inactivation technology that enables us to rapidly inactivate large quantities of a pathogen while retaining epitopes that were destroyed by previous inactivation methods. The method that we call UVC-MDP inactivation can be used to make whole-cell vaccines with increased potency. We and others are exploring the possibility of using improved irradiation-inactivation technologies to develop whole-cell vaccines for numerous antibiotic-resistant microbes. Here, we apply UVC-MDP to produce candidate MRSA vaccines which we test in a stringent tibia implant model of infection challenged with a virulent MSRA strain. We report high levels of clearance in the model and observe a pattern of protection that correlates with the immunogen protein profile used for vaccination.

100 项与 MRSA vaccines (Abcombi Biosciences) 相关的药物交易

登录后查看更多信息